Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
Grant Rauterkus, Mehmet Asım Bilen(Emory Healthcare), Pedro C. Barata(University Hospitals Seidman Cancer Center), Leylah Drusbosky(University of Florida), Syed Arsalan Ahmed Naqvi(Mayo Clinic Hospital), Caroline Weipert(Guardant (United States)), Xīn Gào(Qingdao University), Reagan M. Barnett(Guardant (United States)), Agreen Hadadi(Emory University), Michael B. Lilly(Medical University of South Carolina), Alan H. Bryce(Mayo Clinic Hospital)
Cited by 3
Related Papers
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676